Premium
Prevalence of germline variants in inflammatory breast cancer
Author(s) -
Rana Huma Q.,
Sacca Rosalba,
Drogan Christine,
Gutierrez Stephanie,
Schlosnagle Emily,
Regan Meredith M.,
Speare Virginia,
LaDuca Holly,
Dolinsky Jill,
Garber Judy E.,
Overmoyer Beth A.
Publication year - 2019
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32062
Subject(s) - palb2 , medicine , breast cancer , inflammatory breast cancer , chek2 , genetic testing , oncology , germline , germline mutation , cancer , estrogen receptor , mutation , genetics , gene , biology
Background Inflammatory breast cancer (IBC) is an uncommon and aggressive subtype of breast cancer associated with early disease recurrence and short survival. The prevalence of germline variants in cancer predisposition genes has not been systematically evaluated in women with IBC. Methods Among 301 women enrolled in the clinical IBC registry at a single institution between 2010 and 2017, 168 had documented genetic testing. A second cohort of 200 IBC cases who had panel‐based germline testing performed through a commercial testing laboratory from 2012 to 2017 was added to the analyses. Personal and family cancer histories and genetic testing results were evaluated when they were available for both cohorts. Results Among 501 IBC cases, 368 had documented genetic testing. Germline mutations (56 total) were identified in 53 cases (14.4%). BRCA1 or BRCA2 mutations were found in 7.3% of the subjects, 6.3% had a mutation in other breast cancer genes ( PALB2 , CHEK2 , ATM , and BARD1 ), and 1.6% had mutations in genes not associated with breast cancer. The prevalence of mutations was 24% (22 of 92) among women with triple‐negative IBC, 13% (13 of 99) among women with estrogen receptor– and/or progesterone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative disease, and 9.3% (10 of 108) among women with HER2‐positive IBC. Conclusions The prevalence and diversity of germline genetic mutations among patients with IBC suggest that further studies should be performed to assess the role of inherited mutations in IBC carcinogenesis in comparison with non‐IBC breast cancer. Since IBC has a high metastatic potential associated with poor prognostic outcomes, proposed future studies may also inform targeted treatment options.